187 related articles for article (PubMed ID: 18323166)
1. Quantitative analysis of survivin mRNA expression in bladder transitional cell carcinomas.
Kitsukawa S; Aoyagi T; Noda K; Ito T; Yamamoto Y; Hosoda S; Otsuru N; Matsumoto T
Hinyokika Kiyo; 2008 Feb; 54(2):101-6. PubMed ID: 18323166
[TBL] [Abstract][Full Text] [Related]
2. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
[TBL] [Abstract][Full Text] [Related]
3. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma.
Tsui KH; Cheng AJ; Chang Pe; Pan TL; Yung BY
Urology; 2004 Oct; 64(4):839-44. PubMed ID: 15491744
[TBL] [Abstract][Full Text] [Related]
4. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality.
Shariat SF; Ashfaq R; Karakiewicz PI; Saeedi O; Sagalowsky AI; Lotan Y
Cancer; 2007 Mar; 109(6):1106-13. PubMed ID: 17311310
[TBL] [Abstract][Full Text] [Related]
5. Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence.
Schultz IJ; Kiemeney LA; Witjes JA; Schalken JA; Willems JL; Swinkels DW; de Kok JB
Anticancer Res; 2003; 23(4):3327-31. PubMed ID: 12926071
[TBL] [Abstract][Full Text] [Related]
6. Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction.
Christoph F; Müller M; Schostak M; Soong R; Tabiti K; Miller K
Urology; 2004 Jul; 64(1):157-61. PubMed ID: 15245962
[TBL] [Abstract][Full Text] [Related]
7. Expression of survivin and its spliced variants in bladder tumors as a potential prognostic marker.
Nouraee N; Mowla SJ; Ozhand A; Parvin M; Ziaee SA; Hatefi N
Urol J; 2009; 6(2):101-8. PubMed ID: 19472128
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer.
Moussa O; Abol-Enein H; Bissada NK; Keane T; Ghoneim MA; Watson DK
J Urol; 2006 Jun; 175(6):2312-6. PubMed ID: 16697865
[TBL] [Abstract][Full Text] [Related]
9. Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome.
Hausladen DA; Wheeler MA; Altieri DC; Colberg JW; Weiss RM
J Urol; 2003 Jul; 170(1):230-4. PubMed ID: 12796695
[TBL] [Abstract][Full Text] [Related]
10. Survivin mRNA expression in urine as a biomarker for patients with transitional cell carcinoma of bladder.
Hou JQ; He J; Wen DG; Chen ZX; Zeng J
Chin Med J (Engl); 2006 Jul; 119(13):1118-20. PubMed ID: 16834932
[No Abstract] [Full Text] [Related]
11. Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder.
Elsamman E; Fukumori T; Kasai T; Nakatsuji H; Nishitani MA; Toida K; Ali N; Kanayama HO
BJU Int; 2006 Jun; 97(6):1202-7. PubMed ID: 16686711
[TBL] [Abstract][Full Text] [Related]
12. Expression and antigenicity of survivin, an inhibitor of apoptosis family member, in bladder cancer: implications for specific immunotherapy.
Kitamura H; Torigoe T; Honma I; Asanuma H; Nakazawa E; Shimozawa K; Hirohashi Y; Sato E; Sato N; Tsukamoto T
Urology; 2006 May; 67(5):955-9. PubMed ID: 16635519
[TBL] [Abstract][Full Text] [Related]
13. Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy.
Weiss C; von Römer F; Capalbo G; Ott OJ; Wittlinger M; Krause SF; Sauer R; Rödel C; Rödel F
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1455-60. PubMed ID: 19231102
[TBL] [Abstract][Full Text] [Related]
14. P21-activated kinase 1: a new molecular marker for intravesical recurrence after transurethral resection of bladder cancer.
Ito M; Nishiyama H; Kawanishi H; Matsui S; Guilford P; Reeve A; Ogawa O
J Urol; 2007 Sep; 178(3 Pt 1):1073-9. PubMed ID: 17644138
[TBL] [Abstract][Full Text] [Related]
15. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ.
Sakai I; Miyake H; Harada K; Hara I; Inoue TA; Fujisawa M
Int J Urol; 2006 Nov; 13(11):1389-92. PubMed ID: 17083389
[TBL] [Abstract][Full Text] [Related]
16. Urinary cytokeratin 20 mRNA expression has the potential to predict recurrence in superficial transitional cell carcinoma of the bladder.
Christoph F; Weikert S; Wolff I; Schostak M; Tabiti K; Müller M; Miller K; Schrader M
Cancer Lett; 2007 Jan; 245(1-2):121-6. PubMed ID: 16473461
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer.
Boorjian S; Ugras S; Mongan NP; Gudas LJ; You X; Tickoo SK; Scherr DS
Urology; 2004 Aug; 64(2):383-8. PubMed ID: 15302512
[TBL] [Abstract][Full Text] [Related]
18. Urinary survivin mRNA expression and urinary nuclear matrix protein 22 BladderChek® and urine cytology in the detection of transitional cell carcinoma of the bladder.
Al-Maghrebi M; Kehinde EO; Kapila K; Anim JT
Med Princ Pract; 2012; 21(3):295-7. PubMed ID: 22236881
[TBL] [Abstract][Full Text] [Related]
19. Analysis of hTERT expression in exfoliated cells from patients with bladder transitional cell carcinomas using SYBR green real-time fluorescence quantitative PCR.
Xie XY; Yang X; Zhang JH; Liu ZJ
Ann Clin Biochem; 2007 Nov; 44(Pt 6):523-8. PubMed ID: 17961306
[TBL] [Abstract][Full Text] [Related]
20. Primary application study in early diagnosis of bladder cancer by survivin molecular beacons.
Zhao J; He D; He H; Li L; Zhang LL; Wang XY
Urology; 2007 Jul; 70(1):60-4. PubMed ID: 17656209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
